Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 2Phase NA 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Squamous Cell Carcinoma of Head and Neck 24Head and Neck Neoplasms 21Lung Neoplasms 19Neoplasms 18Stomach Neoplasms 15Urinary Bladder Neoplasms 14Uterine Cervical Neoplasms 11Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Esophageal Neoplasms 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Biliary Tract Neoplasms 10Carcinoma, Transitional Cell 9Triple Negative Breast Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 8Oropharyngeal Neoplasms 7Mesothelioma, Malignant 7Melanoma 7Cholangiocarcinoma 7Carcinoma, Squamous Cell 6Recurrence 5Nasopharyngeal Carcinoma 5Mesothelioma 5Esophageal Squamous Cell Carcinoma 5Carcinoma 5Nasopharyngeal Neoplasms 4Mouth Neoplasms 4

Interventions

Cisplatin 3Cetuximab 3pembrolizumab 2zalutumumab 1temsirolimus 1osimertinib 1cobimetinib 1Taxes 1Sorafenib 1Radiotherapy 1Pemetrexed 1Paclitaxel 1Nivolumab 1Injections 1Fluorouracil 1Cilengitide 1Carboplatin 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Squamous Cell × Cisplatin × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

NCT00401401 2011-12-23

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Genmab

Phase 1/2 Terminated
30 enrolled 13 charts
Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡